Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Staphylococcus Aureus: early-phase trial registry
3 of 10 indexed Staphylococcus Aureus trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,724 of 28,707 conditions by registered trial count.
10 US clinical trials · 3 currently recruiting · #1,724 of 28,707 conditions by registered trial count
Staphylococcus Aureus: 10 US clinical trials tracked, 3 recruiting.
Staphylococcus Aureus is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Johns Hopkins University, running 2 of these trials.
Enrollment posture brief
Registry condition staphylococcus-aureus
OPEN 3 | RECR 30% | LATE 1 | EARLY 5 | RANK #1724 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adrenocortical Carcinoma (30% recruiting · 10 trials)
Staphylococcus Aureus lists 3 open slots (30% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Staphylococcus Aureus on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Staphylococcus Aureus is recruiting below its size-band peers.
3 of 10 indexed trials (30%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Staphylococcus Aureus research.
Johns Hopkins University accounts for 2 of 10 trials (20%). 9 distinct sponsors appear on at least one study for this condition label.
-
Typical Staphylococcus Aureus enrolment sits around 107 participants.
Median target enrolment is 107 among the 9 trials that report a genuine target (sentinel values excluded). 4 of those (44.4%) plan for fewer than 100 participants.
-
Staphylococcus Aureus research is mostly interventional.
8 interventional and 2 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
10 total, page 1 of 1
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
AstraZeneca
NCT06749457
Comparing Single Versus Repeat NMT on the Diversity of the Neonatal Nasal Microbiome
Johns Hopkins University
NCT06283355
Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP
University of Virginia
NCT05094570
Feasibility and Safety Study of Parent-to-Child Nasal Microbiota Transplant
Johns Hopkins University
NCT05695196
Methicillin-resistant Staphylococcus Aureus (MRSA) Skin and Soft Tissue Infection (SSTI) Prevention in Military Trainees
Henry M. Jackson Foundation for the Advancement of Military Medicine
NCT01105767
Risk Factors for Linezolid Resistance in Staphylococcus Aureus
University of Pittsburgh
NCT00519025
A Prospective Cohort Pilot Study of the Clinical and Molecular Epidemiology of Staphylococcus Aureus in Pregnant Women at the Time of Group B Streptococcal Screening in a Large Urban Medical Center in Chicago, IL USA
Ann & Robert H Lurie Children's Hospital of Chicago
NCT00532324
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893 in Healthy Adult Subjects
MedImmune
NCT01769417
Daptomycin in the Treatment of Catheter-Related Staphylococcus Aureus
M.D. Anderson Cancer Center
NCT00507247
Network on Antimicrobial Resistance in Staphylococcus Aureus
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00341913
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Staphylococcus Aureus records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Staphylococcus Aureus trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Staphylococcus Aureus page
10 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Staphylococcus Aureus trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Johns Hopkins University sponsors the most Staphylococcus Aureus trials on record, review their full trial history before evaluating a specific study. See Johns Hopkins University's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Staphylococcus Aureus condition card totals 10 registered trials; most-linked intervention Placebo; top US site state Virginia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.